对乙酰氨基酚诱导的急性肝衰竭的临床与神经学结局:一项21年多中心队列研究
该研究基于ALF研究组登记库,回顾性分析1998-2018年1190例对乙酰氨基酚诱导的急性肝衰竭患者,比较早期(1998-2007)与近期(2008-2018)队列的21天无移植生存率及神经系统并发症。近期队列无移植生存率显著改善(69.8% vs 61.7%,P=.005),颅内高压和脑水肿死亡减少,可能与连续性肾脏替代治疗使用增加有关。
要点
- 近期队列21天无移植生存率显著高于早期队列(69.8% vs 61.7%,P=.005)。
- 近期队列颅内高压发生率显著降低(29.9% vs 51.5%,P<.001),脑水肿死亡减少(4.5% vs 11.6%,P<.001)。
- 多变量模型中连续性肾脏替代治疗与无移植生存率升高相关(比值比1.62,P=.023)。
核心结论
- 近年来对乙酰氨基酚诱导的急性肝衰竭患者无移植生存率改善,颅内高压和脑水肿发生率下降,可能与连续性肾脏替代治疗使用增加有关。
研究设计与样本
- 对前瞻性多中心队列研究(ALF研究组登记库)的回顾性分析,纳入1998-2018年全部1190例对乙酰氨基酚诱导的急性肝衰竭患者,按入组时期分为早期队列(1998-2007)和近期队列(2008-2018)。
主要发现
- 近期队列(n=608)21天无移植生存率为69.8%,早期队列为61.7%(P=.005)。
- 近期队列接受连续性肾脏替代治疗的比例为22.2%,早期队列为7.6%(P<.001)。
- 近期队列颅内高压发生率为29.9%,早期队列为51.5%(P<.001);第21天死于脑水肿的比例分别为4.5%和11.6%(P<.001)。
- 按无移植生存状态分组(非无移植生存组n=365 vs 无移植生存组n=704),精神疾病共病(51.5% vs 55.0%,P=.28)和故意性(故意者39.7% vs 41.6%,P=.58)无差异。
- 多变量logistic回归校正升压药支持、3/4级肝性脑病、King's College标准及MELD评分后,连续性肾脏替代治疗与无移植生存率升高相关(比值比1.62,P=.023,c统计量0.86);近期入组亦与无移植生存率相关(比值比1.42,P=.034,c统计量0.86)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acetaminophen (APAP)-induced acute liver failure (ALF) is a rare disease associated with high mortality rates. This study aimed to evaluate changes in interventions, psychosocial profile, and clinical outcomes over a 21-year period using data from the ALF Study Group registry. METHODS: A retrospective review of this prospective, multicenter cohort study of all APAP-ALF patients enrolled during the study period (1998-2018) was completed. Primary outcomes evaluated were the 21-day transplant-free survival (TFS) and neurologic complications. Covariates evaluated included enrollment cohort (early, 1998-2007; recent, 2008-2018), intentionality, psychiatric comorbidity, and use of organ support including continuous renal replacement therapy (CRRT). RESULTS: Of 1190 APAP-ALF patients, recent cohort patients (n = 608) had significantly improved TFS (recent, 69.8% vs early, 61.7%; P = .005). Recent cohort patients were more likely to receive CRRT (22.2% vs 7.6%; P < .001), and less likely to develop intracranial hypertension (29.9% vs 51.5%; P < .001) or die by day 21 from cerebral edema (4.5% vs 11.6%; P < .001). Grouped by TFS status (non-TFS, n = 365 vs TFS, n = 704), there were no differences in psychiatric comorbidity (51.5% vs 55.0%; P = .28) or intentionality (intentional, 39.7% vs 41.6%; P = .58). On multivariable logistic regression adjusting for vasopressor support, development of grade 3/4 hepatic encephalopathy, King's College criteria, and MELD score, the use of CRRT (odds ratio, 1.62; P = .023) was associated with significantly increased TFS (c-statistic, 0.86). In a second model adjusting for the same covariates, recent enrollment was associated significantly with TFS (odds ratio, 1.42; P = .034; c-statistic, 0.86). CONCLUSIONS: TFS in APAP-ALF has improved in recent years and rates of intracranial hypertension/cerebral edema have decreased, possibly related to increased CRRT use.
引用
- MacDonald AJ, Speiser JL, Ganger DR, et al. Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2020. PMID: 32920216. doi:10.1016/j.cgh.2020.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。